BRIEF-Genmab receives positive opinion from EMA commitee on Arzerra

COPENHAGEN Fri May 23, 2014 9:06am EDT

Related Topics

COPENHAGEN May 23 (Reuters) - Danish biotech company Genmab A/S said on Friday: * GSK and Genmab has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Arzerra in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) who are not eligible for fludarabine-based therapy. * Final decision from European commission expected in the coming months Source text for Eikon: